Test Drive 
, our AI Chatbot - get instant regulatory answers, free and live! Try Now
April 9, 2026 
Dissect the system with an eye towards expediting drug entry into the Japanese market, under new laws and evolving pathways.
When it comes to the currently re-shaping situation in Japanese Regulatory Affairs, companies need to fully understand the transformation and how it will affect their bottomline. This involves both marketing and legal facets. From linguistic requirements to navigating the new bureaucracy, as a drug company, your job is to stay up to date. The system has been streamlined and expedited which is good news, but the know-how with regards to the difference between the Japan drug approval process, is difficult to master.
The foremost problem is understanding what different bodies in Japan do, with respect to regulatory compliance for the life sciences industry in Japan. Whether you are a private sector entity, newly entering the Japanese drug market, or an established company, seeking to stay abreast of the changes, you have to know the differences with regards to purview.
For example, to stay ahead of your competitors, you have to know what the PMDA does and doesn’t do. You have to know what MRCT is and the responsibilities of the MHLW and J-MAH. This article delineates some of this terminology and walks you through regulatory affairs of Japan, from a context-specific standpoint.
The main regulatory body any client will have to deal with, when entering the Japanese market is the PMDA. PMDA stands for Pharmaceutical and medical devices agency. This agency is responsible for post-marketing safety and surveillance, approving new applications from pharmaceutical companies, the analysis of adverse events and also being scientific and medical consultants to the private sector.
Japan offers a comprehensive, standardized process for reviewing new drugs, medical devices entering its market. This process is comprehensive, with a focus on public safety in addition to drug efficacy. However, it’s innovation-friendly, and even provides the expedited Sakigake designation, for pathbreaking products. It’s important to remember, however, that the PMDA has the task of balancing the pace of approvals with the assurance of scientific rigor. They are also constantly updating their expertise, especially with regards to advanced therapies and biologics. This gives this body an opportunity to collaborate internationally as well.
The process involves the post-trial application, known as NDA. The main concentration for PMDA Japan when evaluating the NDA is consistency with regards to quality, whether the drug has side effects and what is the level of efficaciousness. Bear in mind, PMDA also run inspections on manufacturing facilities and coordinate scientific communication with the incoming private sector body. Also, after the approval is granted by the PMDA, the application for new pharmaceuticals entering the Japanese market needs to be assessed by their “Ministry of Health, Labour, and Welfare”. Finally, the NHI, Japan’s system that guarantees National Health Insurance needs to list the drug.
With regards to Japanese regulatory affairs, currently, the PMDA is engaged in digital changes and evolving its decision-making processes by incorporating real-world proof. They also demonstrate a commitment to international harmonization and global collaboration.
Myth No. 1: It is important to remember that the PMDA does not intermediate between Japanese organizations. As a client, please keep in mind that it is not the purview of the PMDA to aid you in finding a Japanese distributor for your product. Instead, the PMDA concentrates mainly on reviewing the entry of medical products into the Japanese market, from a scientific, qualitative and safety standpoint.
Myth No. 2: Also remember that PMDA will not provide access to product information, when those products are being reviewed for market approval. If product classification is the subject of your query, the MHLW is the authoritative body.
Myth No. 3 : It is imperative that submissions regarding the marketing of a new drug in Japan and its relationship to the Japan drug approval process are in Japanese. The marketing-application has to be made using forms that only use the national language of Japan.
Myth No. 4 : As far as MRCTs (Multiregional Clinical Trials) are concerned, the PMDA does not necessarily require a phase I study. In order to gauge whether a Japanese phase I evaluation is required, the PMDA relies on scientific data and merits it case-by-case. This is usually to determine tolerability and pharmacokinetics in test subjects.
Myth No 5 : PMDA is not responsible for adjudicating what type of products are IVDs (In-Vitro Diagnostics). The same goes for medical devices. To make this determination with respect to Japan medical device regulations, clients can contact the in-country Marketing Authorization Holder, commonly referred to as J-MAH. Then, through that entity, they can consult with the local authority that possesses jurisdictional powers, with regards to the J-MAH. They also have the option to get in touch with the MHLW.
According to the National Library of Medicine, between 2008 to 2019, only 20% of the new drugs approved in Japan, were first approved there.
Please bear in mind that there was an amendment to the law passed last year. This amendment was with regards to the PMD Act. The goal of this change was effectuate the expedition of pharmaceutical commerce, provide the pharmacies with more leeway and enhance indigenous product development.
Under the new reform, Responsible Officers of Marketing Authorization Holders can be replaced if such officer has failed to comply with the PMD Act. This is done in order to reduce risk to public health, under the aegis of the MHLW. Also, the MAH is now obligated to appoint a Quality Manager to oversee safety assurance. Another managerial role, Safety Manager, will be selected, with similar duties and responsibilities.
The MAH now also is required to put into place an information collecting plan, to gather and analyze data, with respect to adverse events. Under the changes in the law, a Supply System Manager will be appointed to make sure stability is guaranteed, as far as supply is concerned. This also includes shipment suspensions. In addition, to reduce approval times, marketing authorization holders can now forego notifying the MHLW of changes that pose only moderate risk, and instead opt for expediated 40 day, simplified approval process. Minor changes can be reported annually.
A groundbreaking shift regarding regulatory compliance for the life sciences industry in Japan, involves a conditional approval for drugs, I-VD products and even medical devices, whose effectiveness can be noticed or gauged at the exploratory phase. The result is a mitigation of the lag when it comes to the Japan drug approval process.
The landscape has also been reshaped by other developments like 40 label changes of a partial nature. This has transformed patient access and even improved access for clinicians. Priority review procedures and advisory support have also beneficially affected designations for rare-diseases and orphan-drugs.
The landscape has evolved to such a degree that between April of 2024 and March of 2025, 148 approval decisions were made and 66 active ingredients were newly updated. Even lifecycles saw 82 updates (indications, changes in formulations, pediatric expansions).
From the standpoint of the companies themselves, this shift in the landscape offers multiple advantages. Firstly, they can utilize RWD (Real-world Data), that includes electronic records of health and patient registries. Secondly, they can bypass traditional clinical trials in favor of RWD, when it comes to label expansions. Thirdly, the PMDA Japan has reformed into a model that favors data, thereby allowing companies involve “‘real-world’” evidence into the post-market surveillance process. This permits a more robust patient-centric safety system and continuous monitoring. This also improves speed with which the treatments and innovations benefit patients, whilst keeping track of rigor. Ultimately, what you, the client, is left with, is reduced market times and more malleable pathways for development. But keep in mind that this changing landscape requires a strong comprehension of indigenous requirements of the Japanese market.
Companies need to be on top of strategies for patient safety, QPPV, understanding case processing with respect to pharmacovigilance under Japanese law, know how to file local reports, get help from experts in technical writing, understand regulatory submissions within the Japanese legal framework. Specifically, companies need consultation when it comes to how to deal with the PMDA. A bilingual team, is helpful in that regard. The consultation offered must be tailored not just to the needs of the company, but also MHLW Japan regulations. This also include J-NDA submissions, strategy for development, expertise on local matters, providing vigilance on safety practices, at an end to end level.
In this evolving landscape, companies need to navigate the nuances of culture whilst keeping an eye on the newer legal changes. They need to respond to the enquiries of PMDA Japan, at a reasonable rate, plan early and engage with some degree of continuity. Bear in mind that the Japanese regulatory body requires ongoing reporting of safety issues at a post-market level, reporting on adverse events is critical, cooperation with systemic re-examination known as EPPV. This means “‘Early Postmarketing Phase Vigilance’”. Compliance will be required with a process known as “‘Good Post-Marketing Study Practice’”.
Pro – Tip : To synergize cooperation with Japanese Regulatory systems, read and learn their guidelines, using human or AI readers.
As a company, remember that under the new system, you have to use the eCTD platform. This stands for electronic Common Technical Document. This is a requirement. The good news is this allows for a much stronger framework data organization, much better clarity and transparency in terms of compliance submissions.
When it comes to the regulatory affairs of Japan, bear in mind that going forward the criteria for validating whether documents submitted are accurate and comprehensive, will be stricter. Be very thorough and pay attention to formatting, structure of the metadata and specifications of a technical nature.
As a company trying to deliver drugs to the Japanese consumer base, keep in the mind that you need to stay on top of any gaps with regards to the eCTD v4.0 system. This involves keeping the eCTD software up to date and maintain the upkeep and validation thereof. You need to train your human staff to oversee the eCTD system and keep track of how the new changes ramify with respect to regulatory submissions.
Having an all-encompassing knowledge of the Japanese regulatory system for pharmaceuticals is vital to successfully meeting all legal and commerce requirements of the Japanese market. Therefore, make sure you take part in pilot programs organized by the PMDA and start a phased and planned migration to complete compliance.
As a company, it is important for you to learn as much as you can about the recent laws passed, in terms of how this revitalizes the Japanese regulatory system for pharmaceuticals. Educating the workplace staff on MHLW Japan regulations, is crucial to streamline and speed up the entry into the Japanese market. As mentioned before, the legal changes make many aspects of balancing compliance with the Japan drug approval process easier, while offering a new set of issues. The key to navigate regulatory affairs in the context of Japan is to thoroughly understand and interpret the ramifications of the recent regulations, from a cultural and commercial point of view.
As Japan’s regulatory landscape continues to evolve, staying ahead is about having the right intelligence at your fingertips. With the right regulatory intelligence platform, you can turn complex updates into clear, actionable strategies and accelerate market entry with confidence.
If you’re looking to simplify compliance and stay proactive, book a demo today and see how smarter regulatory intelligence can transform your approach.
Get your regulatory dose of information delivered straight to your inbox every month!
Subscribe Now
